Related Experiment Video
Updated: Jun 17, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions
Adam Shapira Levy1, Jean-Paul Bryant2,3, David Matichak4
1Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL 33176, USA.
Abstract:
The Mitogen-activated protein kinase kinase (MEK) protein family has dual-specificity protein kinases with a myriad of cellular functions that include but are not limited to cell survival, cell division, immunologic response, angiogenesis, and cellular senescence. MEK is crucial in the MAPK signaling pathway, regulating different organ systems, including the CNS. Increased activation and dysregulation of the MEK pathway is reportedly observed in 30% of all malignancies. The diversity of MEK renders it a prime target for inhibition in treating cancer. MEK inhibition has been studied in the context of melanoma, non-small cell lung cancer, breast cancer, and colorectal cancer, among others. The standard treatment for glioblastoma (resection, temozolomide, and radiation) remains relatively futile, which warrants alternative treatment options. Therefore, MEK inhibition has garnered more attention in recent years as investigators have explored its role in treating the most aggressive and most common primary brain tumor, glioblastoma. MEK inhibitors have shown efficacy in pre-clinical investigations as well as some promise in clinical trials which have demonstrated improved overall and progression-free survival. This underscores the potential of MEK inhibition in glioblastoma therapy and represents an area that likely warrants further research. However, there are few comprehensive and unifying reviews discussing the current state of MEK inhibition in glioblastoma therapy. We begin this review by detailing the normal function of MEK as it pertains to the CNS. We then compiled relevant pre-clinical and clinical studies to investigate recent research discussing the role of MEK inhibition in glioblastoma therapy.
Insights
Mitogen-activated protein kinase kinase (MEK) inhibition is a promising strategy for glioblastoma treatment. MEK inhibitors show efficacy in pre-clinical and clinical studies, offering potential for improved survival in this aggressive brain cancer.
Area of Science:
- Oncology
- Molecular Biology
- Neuro-oncology
Background:
- Mitogen-activated protein kinase kinase (MEK) proteins are vital in cellular functions including survival and division.
- Dysregulation of the MEK pathway is implicated in numerous cancers, making it a key therapeutic target.
- Standard glioblastoma treatments are often ineffective, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review the role of MEK inhibition in glioblastoma therapy.
- To consolidate current pre-clinical and clinical research on MEK inhibitors for glioblastoma.
- To highlight MEK inhibition as a potential therapeutic strategy for glioblastoma.
Main Methods:
- Compilation of pre-clinical investigation data.
- Analysis of clinical trial outcomes.
- Review of existing literature on MEK pathway and glioblastoma.
Main Results:
- MEK inhibitors have demonstrated efficacy in pre-clinical models of glioblastoma.
- Clinical trials indicate that MEK inhibitors can improve overall and progression-free survival.
- MEK pathway dysregulation is common in glioblastoma, supporting targeted inhibition.
Conclusions:
- MEK inhibition represents a promising therapeutic avenue for glioblastoma.
- Further research into MEK inhibitors is warranted to optimize glioblastoma treatment.
- MEK inhibitors offer a potential alternative to current, often futile, glioblastoma therapies.
